Wang allegedly obtained approximately $16 million in grants fraudulently from the National Institutes of Health.
The grants Wang received, totaling around $16 million, were intended to fund scientific research for a potential treatment and diagnostic test for Alzheimer's disease. The research involved the early developmental phases of a proposed drug and diagnostic test, with the funding supporting Wang's laboratory work and salary1.
The drug's research linked to Wang's studies is simufilam, an experimental Alzheimer's therapy being tested in late-stage clinical trials by Cassava Sciences. Wang's work, which has been under scrutiny for potential fabrication and falsification of data, provided the scientific basis for simufilam's development.